Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
Simplified Insulin Regimen for the Elderly
- Conditions
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 7
- Registration Number
- NCT03660553
- Locations
- 🇺🇸
University of Miami, South Miami, Florida, United States
A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Geropharm
- Target Recruit Count
- 28
- Registration Number
- NCT03604575
- Locations
- 🇷🇺
LLL "BioEq", Saint Petersburg, Russian Federation
Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 67
- Registration Number
- NCT03509324
- Locations
- 🇨🇳
endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT03465878
- Locations
- 🇨🇦
LMC Endocrinology Centres Ltd., Toronto, Ontario, Canada
🇩🇪Kinderkrankenhaus auf der Bult, Hannover, Niedersachsen, Germany
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT03449433
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 49
- Registration Number
- NCT03433677
- Locations
- 🇺🇸
Valley Research, Fresno, California, United States
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville, Spain
🇺🇸Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT03407118
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Fukuoka, Japan
Assessment of Mealtime Bolus Insulin Behavior
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 79
- Registration Number
- NCT03368807
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸AMCR Institute, Inc., Escondido, California, United States
🇺🇸Science 37 Inc, Los Angeles, California, United States
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT03367390
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Renton, Washington, United States
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 272
- Registration Number
- NCT03338023
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Guangdong Province People's Hospital, Guangzhou, Guangdong, China
🇨🇳Wu Han Tongji Hospital, Wu Han, Hu Bei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.